According to research published online January 1, 2014 in the New England Journal of Medicine, a new drug called romosozumab may offer hope for the treatment of osteoporosis. The drug works by freeing the body’s ability to stimulate bone production by blocking signals that naturally inhibit bone formation. According to
Over a lifespan, celiac disease symptoms tend to shift from primarily gastrointestinal ones in children (diarrhea, bloating, pain) to “non-classical” or “subclinical” ones in adults (fatigue, anemia, arthritis, and numbness/tingling in the fingers and toes). Non-classical symptoms can make celiac disease harder to spot, particularly if a patient has other
Because your jaw is one of the joints you use most often, dealing with jaw pain can be difficult—it can affect your ability to talk and eat. Often, jaw pain is related to problems with your teeth resulting from an oral health issue or from a habit like teeth-grinding.
In the past two decades, several medications have received FDA approval for the treatment and/or prevention of osteoporosis. With so many choices, which ones are the most effective, and what do we know now about these drugs that we didn’t know 20 years ago?
“We know that using bisphosphonates in the
With up to 54 million Americans suffering from low bone density or osteoporosis, development of a new drug to combat the condition is timely. The new therapy, a dietary supplement that is a special blend of collagen and calcium, called KoACT®, in clinical trials was found superior to calcium and
Bisphosphonate drugs are medications designed to treat osteoporosis by increasing bone density. The first bisphosphonate was approved by the US Food and Drug Administration in 1995. However, ongoing safety reviews have revealed concerns about effects from long-term bisphosphonate use, which have been linked with a small (less than one percent)
Bisphosphonates (BP) were initially developed in the 1960s, but their use in arresting bone loss began in the 1990s. They are the most commonly used medication for osteoporosis—in the U.S. alone, osteoporosis results in 1.5 million fractures per year. Alendronate (Fosamax) was the first BP drug commercially available to treat
Your bones are your body’s framework—and for many, the bone-building drugs bisphosphonates ensure a sound foundation against the impact of osteoporosis. Bisphosphonates, including the oral drugs alendronate (Fosamax®), risedronate (Actonel®) and ibandronate (Boniva®), and the intravenously (IV) administered zoledronic acid (Reclast®), have been shown to reduce the risk for fracture
When the drug companies themselves start recommending “drug holidays” for certain osteoporosis patients to reduce the risk of serious bisphosphonates side effects, it’s time to take notice.
What if you knew a common treatment approach has been shown to actually increase the risk of bone fractures? That is almost as sad as the antidepressant drugs having increased risk of suicide as one of their side effects.